Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease

Francesco Grimaldi, MD, Pilar Perez-Abellan, Steven Best, PhD, Nicholas Lea, PhD, John Veluchamy, Muhammad Atif, MD, Rosemary Grain, Monica Sen, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Victoria T Potter, MD FRCPA, FRACP, Ghulam J Mufti, FRCP, FRCPath, Judith C.W. Marsh, MD, Linda D Barber, PhD

Blood (2015) 126 (23): 3129.

https://doi.org/10.1182/blood.V126.23.3129.3129

Published: 2015

Journal Articles

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

Francesco Grimaldi, MD, Linda D Barber, PhD, Pilar Perez-Abellan, MSc, Rosemary Grain, Victoria T Potter, MD FRCPA, FRACP, Austin Kulasekararaj, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Judith C Marsh, MD

Blood (2014) 124 (21): 1594.

https://doi.org/10.1182/blood.V124.21.1594.1594

Published: 2014

Journal Articles

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Susanne Isfort, MD, Jasmin Bahlo, Raymonde Busch, Petra Langerbeins, MD, Anna-Maria Fink, MD, Valentin Goede, MD, Thomas Elter, MD, Manuela A. Bergmann, MD, Martina Beate Stauch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Michael Hallek, MD PhD, Barbara F. Eichhorst, MD

Blood (2012) 120 (21): 3936.

https://doi.org/10.1182/blood.V120.21.3936.3936

Published: 2012

Journal Articles

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, Enrica Morra

Blood (2011) 118 (15): 4079–4085.

https://doi.org/10.1182/blood-2011-05-351833

Published: 2011

Journal Articles

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Marco Montillo, MD, Alessandra Tedeschi, Francesca Ricci, Alfonso Zaccaria, Monica Crugnola, Mauro Spriano, PierAngelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Angelo De Blasio, Eleonora Vismara, Enrica Morra, Valeria Belsito Petrizzi

Blood (2010) 116 (21): 1384.

https://doi.org/10.1182/blood.V116.21.1384.1384

Published: 2010

Journal Articles

Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment.

Judith C W Marsh, Vikas Gupta, ZiYi Lim, MD, David Marks, Edward C. Gordon-Smith, MD, BM, BCh, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 1084.

https://doi.org/10.1182/blood.V114.22.1084.1084

Published: 2009

Journal Articles

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Eleonora Vismara, MD, Denis Ciapanna, MD, Valeria Belsito Petrizzi, MD, Monica Crugnola, MD, Mauro Spriano, MD, Lilj Uziel, MD, Angelo De Blasio, MD, Pierangelo Spedini, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3133.

https://doi.org/10.1182/blood.V110.11.3133.3133

Published: 2007

Journal Articles

Efficacy of Performing a Second Non-Myeloablative Allogenic Stem Cell Transplant.

Brian J. Byrne, MD, Joseph H. Antin, MD, Edwin P. Alyea, MD, Nelson J. Choa, MD, David A. Rizzieri, MD

Blood (2005) 106 (11): 3664.

https://doi.org/10.1182/blood.V106.11.3664.3664

Published: 2005

NARROW

King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment.

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Efficacy of Performing a Second Non-Myeloablative Allogenic Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only